Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INVEST-CI Study II: Intravenous Autologous Bone Marrow–Derived MSCs for Cerebral Infarction
jRCT2091220118Recruiting
- Sponsor
- Osamu Honmou, MD, PhD
- Start
- Mar 2013
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of autologous bone marrow derived mesenchymal stromal cells in brain infarction and ischemic stroke, sponsored by Osamu Honmou, MD, PhD. Primary endpoint: Safety: all adverse events rate during whole study period. Started Mar 2013; status: recruiting.
02
Drugs
autologous bone marrow derived mesenchymal stromal cells
03
Conditions
brain infarctionischemic stroke
Beyond the preview
Go deeper on jRCT2091220118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2091220118.